Brief Introduction

Zhejiang Orient Gene Biotech Co., Ltd, founded in December 2005, listed on SSE STAR MARKET on Feb. 5th, 2020. We specialize in R&D, production and sales of in vitro diagnostic products, and insist on the application of the cutting-edge "genetic engineering" technology to product development and industrial layout. Orient gene is accelerating the industrialization and marketing process of its three core platforms: POCT rapid diagnostics, molecular diagnostics and liquid biochips.

POCT rapid diagnostics is the current flagship product line of Orient Gene. We offer hundreds of POCT instant diagnostics assorted into five categories: Infectious Disease (including COVID-19 Test series), Drug of Abuse, Pregnancy and Fertility,Cardiac Marker and Tumor Marker.The products are exported to more than 100 countries and regions worldwide, with overseas sales accounting for about 95%. At present, Orient Gene has a complete industry chain covering from raw material, POCT diagnostics to rapid diagnostic instruments, and will focus on the industrial upgrading from "product provider" to "product provider and third-party testing".

Confronting the COVID-19 outbreak in 2020, orient gene has responded quickly to the demand for epidemic test and made efforts tosupport the fight against the epidemic. We have developed a series of COVID-19 testreagents which have been widely recognized by the market.Orient Gene has become one of the key exporters of COVID-19 test reagents in China, accounted for approximately 16% of the total export volume of the country.

Company Overview

Full name Zhejiang Orient Gene Biotech Co., Ltd
Abbreviations Orient Biotech
Code 688298
Founded 2005-12-01
Listing 2020-02-05
Domicile Anji, Zhejiang, China
STAR Theme Biomedicine
CSRC Sector Biomedicine Manufacturing(C27)
Has weighted voting rights structure? No



  2020 2019 2018
Earnings Per Share 14.28 0.91 0.73
R&D expenditure as a % of operating revenue 2.87% 8.64% 6.52%
Operating Revenue 3,265.36 million 367.38 million 285.89 million
Net Income 1,680.33 million 77.51 million 63.96 million

Income Statement (Unit: RMB mn)

  2020 2019 2018
Operating Revenue 3,265.36 367.38 285.89
Operating Costs 677.78 192.85 146.75
Operating Income 1,974.35 91.03 75.16
Pretax Income 1,974.28 91.30 77.00
Income Tax 293.95 13.79 13.04
Net Income 1,680.33 77.51 63.96

Balance Sheet(Unit: RMB mn)

  2020 2019 2018
Current Assets-Total 3,319.34 259.69 243.72
Non-current Assets-Total 253.88 101.82 93.93
Total Assets 3,573.22 361.51 337.65
Current Liabilities-Total 1,113.01 91.52 121.26
Non-current Liabilities-Total 8.80 15.87 8.36
Total Liabilities 1,121.81 107.38 129.62
Stockholder's Equity
Share Capital 669.21 118.39 118.39
Retained Profits 1,776.83 133.33 82.64
Total Owners' Equity 2,451.41 254.13 208.03

Cash Flow Statement (Unit: RMB mn)

  2020 2019 2018
Net Cash Flows-Operating 1,790.31 54.21 44.33
Net Cash Flows-Investing -548.84 -11.73 -18.75
Net Cash Flows-Financing 503.29 -60.29 -5.72

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
安吉福浪莱进出口贸易有限公司 23.40 19.50%
Fangs Holdings Limited Liability Company 22.50 18.75%
Shanghai XiangheyongAn Equity Investment Partnership Enterprise (LP) 12.59 10.49%
安吉涌威投资合伙企业(有限合伙) 12.37 10.31%
浙江永石股权投资合伙企业(有限合伙) 8.27 6.90%
上海豪贤实业发展合伙企业(有限合伙) 2.25 1.88%
Shanghai Yongchuanghuaxing Investment Partnership Enterprise (LP) 1.87 1.56%
Everbright Fortune Investment Co.,Ltd. 1.38 1.15%
Lianyungang Yongcheng Equity Investment Partnership Enterprise (LP) 0.93 0.78%
上海永石企业发展合伙企业(有限合伙) 0.86 0.71%
As of 2021-03-31

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.